Search results for "Colitis"

showing 10 items of 483 documents

Desarrollo de formulaciones de liberación controlada para enfermedades inflamatorias

2022

Las enfermedades inflamatorias con componente autoinmune de la piel y del tracto gastrointestinal, como son la psoriasis y la dermatitis atópica y la enfermedad inflamatoria intestinal, respectivamente, son enfermedades prevalentes que necesitan mejorar su tratamiento. La ciclosporina A es un fármaco inmunosupresor que ha demostrado ser efectivo para el tratamiento de enfermedades autoinmunes, pero también sus efectos adversos a nivel sistémico. En el caso de las enfermedades cutáneas, la administración por vía tópica de este fármaco aportaría grandes ventajas como la posibilidad de actuar a nivel local y evitar efectos sistémicos. Sin embargo, la ciclosporina A presenta un tamaño molecular…

liberación controladaliposomasUNESCO::CIENCIAS MÉDICASpsoriasisenfermedad inflamatoria intestinaldermatitis atópicananopartículasmicropartículascolitis ulcerosa
researchProduct

2007

medicine.anatomical_structurebusiness.industryLymphocyteImmunologyMedicineMurine colitisSurgerybusinessJournal of Surgical Research
researchProduct

COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinants in a National Survey of the Ita…

2021

The coronavirus disease 2019 (COVID-19) pandemic has not finished yet, and the most promising option towards its ending is widespread vaccination. Because patients with inflammatory bowel diseases (IBDs), namely Crohn’s disease (CD) and ulcerative colitis (UC), often require immune-modifying treatment, which might increase the risk of opportunistic infection,1 their vaccination history for several infectious diseases is routinely checked, and when inadequate, vaccination is performed at diagnosis or ideally before immune suppressive treatment is started.1 However, IBD patients were not found to be at an increased risk of developing COVID-19 or of experiencing a more severe disease course.2

medicine.medical_specialty2019-20 coronavirus outbreakCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)IBDBrief Report - ClinicalInternal medicinemedicineHumansImmunology and AllergyIn patientAcademicSubjects/MED00260SARS-CoV-2business.industryVaccinationGastroenterologyCOVID-19Inflammatory Bowel DiseasesInflammatory Bowel DiseasesCOVID-19 Vaccines HumanVaccinationIBD Crohn Ulcerative Colitis Vaccination Covid 19 Sars-Cov 2COVID-19; COVID-19 vaccine; IBD; vaccine hesitancyvaccine hesitancybusinessCOVID-19 vaccineInflammatory Bowel Diseases
researchProduct

Postoperative maintenance therapy for inflammatory bowel disease.

2006

. Curr Opin Gastroenterol. 2006 Jul;22(4):377-81. Postoperative maintenance therapy for inflammatory bowel disease. Cottone M, Orlando A, Modesto I. Department of General Medicine, Pneumology and Nutrition Clinic, Palermo University, Palermo, Italy. PURPOSE OF REVIEW: This review will highlight the knowledge gained from studies published in the year 2005 on maintenance treatment after surgery for inflammatory bowel diseases. RECENT FINDINGS: In Crohn's disease the role of smoking in increasing the risk of relapse and recurrence after surgery is confirmed. Ornidazole seems effective in reducing endoscopic recurrence and clinical relapse after surgery. Probiotics do not appear to be effective…

medicine.medical_specialtyAzathioprineInflammatory bowel diseaseEnteral NutritionMaintenance therapymedicineHumansIntensive care medicineDigestive System Surgical Procedurescrohn.post-operative.Postoperative CareCrohn's diseasebusiness.industryProbioticsGastroenterologyRetrospective cohort studyPouchitismedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisSurgeryAnti-Bacterial AgentsParenteral nutritionTreatment OutcomebusinessImmunosuppressive Agentsmedicine.drugCurrent opinion in gastroenterology
researchProduct

Oral administration of taurolidine ameliorates chronic DSS colitis in mice.

2007

Taurolidine (TRD) has antimicrobial and anti-inflammatory properties. However, the anti-inflammatory effects of TRD in inflammatory bowel diseases (IBD) have not been investigated. Here, we have analyzed the toxicity of TRD after oral long-term application in mice and examined the impact of oral TRD in a dextran sulfate sodium (DSS) model of experimental colitis. Female C57/BL6 mice received TRD in various concentrations (0.1% to 0.4%) for 60 days. Toxicity was evaluated by use of a disease activity index (DAI) and histological examination of major metabolic organs. Furthermore, the impact of 0.2% TRD on a chronic DSS colitis was examined by daily DAI, histological crypt damage score (CDS),…

medicine.medical_specialtyColonTaurineAdministration OralGastroenterologyInflammatory bowel diseasechemistry.chemical_compoundMiceOral administrationInternal medicinemedicineMesenteric lymph nodesAnimalsColitisThiadiazinesbusiness.industryDextran SulfateInterleukinTaurolidinemedicine.diseaseColitisInflammatory Bowel DiseasesMice Inbred C57BLmedicine.anatomical_structurechemistryCyclooxygenase 2Bacterial TranslocationImmunologyToxicityCytokinesSurgeryTumor necrosis factor alphaFemaleLymph NodesbusinessJournal of investigative surgery : the official journal of the Academy of Surgical Research
researchProduct

Virtual chromoendoscopy with iSCAN as an alternative method to dye-spray chromoendoscopy for dysplasia detection in long-standing colonic inflammator…

2021

Patients with long-standing colonic inflammatory bowel disease (cIBD) are at increased risk of developing colorectal cancer (CRC). Dye-spray chromoendoscopy (DCE) with targeted biopsies is the preferred technique for surveillance of dysplasia. Virtual chromoendoscopy (VCE) are arising to improve detection rates and adherence to surveillance guidelines, although its role is not yet well defined. The purpose of this study is to assess the effectiveness of VCE with iSCAN as an alternative method for dysplasia detection in cIBD.Retrospective case-control study with 191 patients included, 98 in the DCE (Indigo carmine) group and 93 in the VCE (iSCAN, twin-mode 1-3) group. The dysplasia detection…

medicine.medical_specialtyColorectal cancerColonoscopyInflammatory bowel diseaseGastroenterologyChromoendoscopy03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansColoring Agentsskin and connective tissue diseasesEarly Detection of CancerRetrospective StudiesAlternative methodsmedicine.diagnostic_testbusiness.industryGastroenterologyCase-control studyColonoscopyInflammatory Bowel Diseasesmedicine.diseasedigestive system diseasesIncreased riskDysplasiaCase-Control Studies030220 oncology & carcinogenesisColitis Ulcerative030211 gastroenterology & hepatologyColorectal NeoplasmsbusinessScandinavian Journal of Gastroenterology
researchProduct

Mesalazine for the treatment of inflammatory bowel disease

2013

Ulcerative colitis (UC) and Crohn's disease (CD) represent a chronic inflammatory condition of the bowel that often require lifelong medical therapy for the induction and maintenance of the remission. Mesalazine therapies are available both as oral delayed-release and sustained-release formulation, topical formulations and as prodrug.Available literature regarding mesalazine is extensively reviewed in this article, covering its mechanism of action, pharmaceutics and pharmacokinetics, clinical efficacy, safety and tolerability in different settings.Mesalazine has a well-established role in the management of UC. It is the treatment of choice in active and inactive mild-to-moderate UC combinin…

medicine.medical_specialtyColorectal cancerDiseaseGastroenterologyInflammatory bowel diseasechemistry.chemical_compoundCrohn DiseaseMesalazineInternal medicineSecondary PreventionmedicineHumansPharmacology (medical)Intestinal MucosaColitisMesalaminePharmacologyCrohn's diseasebusiness.industryAnti-Inflammatory Agents Non-SteroidalGeneral Medicinemedicine.diseaseUlcerative colitischemistryTolerabilityColitis UlcerativeColorectal NeoplasmsbusinessExpert Opinion on Pharmacotherapy
researchProduct

The Selective Use of Combination Therapy in Patients with Inflammatory Bowel Disease Resistant to Anti-TNF: to Whom, How and How Long?

2016

Sir, We read with interest the recent work by Peyrin-Biroulet and colleagues on the long-term outcome for patients starting anti-TNF monotherapy for Crohn’s disease [CD] and for those needing the addition of an immunomodulator [IM].1 We agree with the main finding of the study, i.e. starting with anti-TNF monotherapy does not worsen long-term disease outcomes. This is in line with data from the literature2 and with our recent prospective study on the concomitant use of an IM and infliximab [IFX] in patients with CD or ulcerative colitis who have had a primary or secondary non-response to IFX monotherapy3: …

medicine.medical_specialtyCombination therapyDiseaseInflammatory bowel diseaseGastroenterology03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansImmunologic FactorsTreatment FailureProspective cohort studyCrohn's diseasebusiness.industryGastroenterologyGeneral Medicinemedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisInfliximabInfliximab030220 oncology & carcinogenesisConcomitantImmunology030211 gastroenterology & hepatologyDrug Therapy Combinationbusinessmedicine.drugJournal of Crohn'scolitis
researchProduct

Response to "The combination therapy with cytapheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous An…

2018

medicine.medical_specialtyCombination therapymedicine.drug_class030204 cardiovascular system & hematologyAntibodies Monoclonal HumanizedGastroenterologyVedolizumab03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesInternal medicinemedicineHumansColitisHepatologybusiness.industryTumor Necrosis Factor-alphaGastroenterologymedicine.diseaseUlcerative colitisCytapheresisMonoclonalCorticosteroidTumor necrosis factor alphaColitis UlcerativebusinessCytapheresis030215 immunologymedicine.drugDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Cytomegalovirus Pneumonia: A Possible Cause of Death in Patients With Crohn's Disease

2013

.

medicine.medical_specialtyCrohn's diseaseGastrointestinal agentCytomegalovirus pneumoniaHepatologyCrohn diseasebusiness.industryGastroenterologymedicine.diseaseCytomegalovirus Cytomegalovirus Infections ColitisGastroenterologyCytomegalovirus pneumonia Crohn’s diseaseAntibodies monoclonalInternal medicinemedicineIn patientbusinessCause of deathAmerican Journal of Gastroenterology
researchProduct